• 16 May 2013

    Sonendo®, a developer of a revolutionary technology for the endodontic marketplace, unveiled its new Multisonic Ultracleaning™ System at the recent American Association of Endodontists (AAE) in Hawaii, a national, member-based organization dedicated to endodontic education.

  • 13 May 2013

    Endosense, a pioneer and leader in contact force (CF) technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, further advanced its leadership position in the field with new study data validating the importance of several proprietary contact force parameters, including its most recently developed Lesion Index (LSI™). Unveiled in abstracts at the Heart Rhythm 2013 held last week in Denver, the data also demonstrated the ability of the company’s TactiCath® ablation catheter to detect excessive contact force during robotic catheter navigation.

  • 10 May 2013

    Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis’ LSE (Low Systemic Exposure) technology that creates ‘topical-by-design’ drugs.

  • 24 April 2013

    Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, for inflammation and pain, today announces that it has been awarded a prestigious European Union Framework Programme 7 (FP7) grant in the ‘Health: Systems Medicine’ work programme theme. The €1.98m FP7 grant will be used to develop the next generation of Creabilis’ ‘topical-by-design’ pre-clinical candidates to complement its existing clinical portfolio. The candidates will be developed using Creabilis’ proprietary Low Systemic Exposure (LSE) technology.

  • 26 March 2013

    Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that the results of its EFFICAS I prospective multi-center study have led to the development of guidelines for target and minimumcontact force (CF), as well as minimum Force Time Integral (FTI™), during the catheter ablation treatment of paroxysmal atrial fibrillation (PAF). Published in the April 2013 issue of the American Heart Association journal Circulation: Arrhythmia and Electrophysiology, the newly created guidelines call for a CF target of 20 g (and minimum CF of 10 g) and minimum FTI of 400 gs per individual ablation lesion.